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OBJECTIVE—Glycemia is a major risk factor for the develop-
ment of long-term complications in type 1 diabetes; however, no
speciﬁc genetic loci have been identiﬁed for glycemic control in
individuals with type 1 diabetes. To identify such loci in type 1
diabetes, we analyzed longitudinal repeated measures of A1C
from the Diabetes Control and Complications Trial.
RESEARCH DESIGN AND METHODS—We performed a ge-
nome-wide association study using the mean of quarterly A1C
values measured over 6.5 years, separately in the conventional
(n  667) and intensive (n  637) treatment groups of the DCCT.
At loci of interest, linear mixed models were used to take
advantage of all the repeated measures. We then assessed the
association of these loci with capillary glucose and repeated
measures of multiple complications of diabetes.
RESULTS—We identiﬁed a major locus for A1C levels in the
conventional treatment group near SORCS1 (10q25.1, P  7 
10
10), which was also associated with mean glucose (P  2 
10
5). This was conﬁrmed using A1C in the intensive treatment
group (P  0.01). Other loci achieved evidence close to genome-
wide signiﬁcance: 14q32.13 (GSC) and 9p22 (BNC2)i nt h e
combined treatment groups and 15q21.3 (WDR72) in the inten-
sive group. Further, these loci gave evidence for association with
diabetic complications, speciﬁcally SORCS1 with hypoglycemia
and BNC2 with renal and retinal complications. We replicated
the SORCS1 association in Genetics of Diabetes in Kidneys
(GoKinD) study control subjects (P  0.01) and the BNC2
association with A1C in nondiabetic individuals.
CONCLUSIONS—A major locus for A1C and glucose in individ-
uals with diabetes is near SORCS1. This may inﬂuence the design
and analysis of genetic studies attempting to identify risk factors
for long-term diabetic complications. Diabetes 59:539–549,
2010
E
levation in plasma glucose, as measured by A1C,
is a major risk factor for long-term diabetic
complications (1–13). Twin and family studies
have shown that A1C levels are heritable in
nondiabetic individuals (14–16). In addition, signiﬁcant
correlation in A1C between monozygotic twins both con-
cordant and discordant for type 1 diabetes (14,17), as well
as in siblings with type 1 diabetes (18,55), suggests that
some genetic factors inﬂuence A1C in both diabetic and
nondiabetic individuals. However, no study of dizygous
twins has been performed. These observations have moti-
vated genome-wide linkage studies of measures of glyce-
mia (typically single fasting plasma glucose or A1C),
predominantly in nondiabetic individuals, but have not led
to the identiﬁcation of novel genes possibly because of
small effect sizes of individual loci and underpowered
studies (15,19,20). More recently, association studies of
fasting glucose in nondiabetic individuals have identiﬁed
multiple loci that meet genome-wide signiﬁcance criteria
(P  5  10
8, supplementary Table 1, available in an
online appendix at http://diabetes.diabetesjournals.org/cgi/
content/full/db09-0653/DC1) (20–29).
In individuals with type 1 diabetes, there is considerable
variability in glycemic control both between and within
individuals. Intra-individual variation is likely caused by
changes in diabetes management (e.g., pump versus mul-
tiple daily injections [30]), diet, activity, weight control,
and insulin dosing in response to glucose and A1C mea-
sures. Other factors that may inﬂuence A1C are erythro-
cyte turnover, hemoglobinopathies, defects of glucose
transport into erythrocytes, mechanisms of glycation and
de-glycation, and alterations in intracellular glucose me-
tabolism. Speciﬁcally, in the conventional treatment arm
of the Diabetes Control and Complications Trial (DCCT),
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A1C values was 0.79, falling to 0.42 for values measured 3
years apart. In the face of such high variability over time,
analyzing longitudinally repeated measures via mixed
models can increase power to identify risk factors. Alter-
natively, taking the mean of the values over time may be
sufﬁcient to initially screen for important genetic effects.
We hypothesized that common genetic variants associated
with glycemic control in subjects with type 1 diabetes
could be identiﬁed using repeated measures of A1C from
subjects in the DCCT. Because glycemic control was the
major intervention in DCCT, we performed genetic analy-
sis separately in each treatment group, with the expecta-
tion that genetic effects may be larger in the conventional
treatment group in which there was no attempt to alter A1C
(apart from preventing very high values [i.e., 13.11%]).
RESEARCH DESIGN AND METHODS
DCCT subjects. A total of 1,441 patients with type 1 diabetes were recruited
for the DCCT (1,31), which was designed to determine if intensive diabetes
management, with the goal of normalizing glycemic levels, would prevent or
delay the development and/or progression of long-term diabetic complica-
tions. At screening for eligibility, A1C had to be 6.6%, and subjects with
hemaglobinopathies were excluded (31). Subjects were randomized to either
conventional therapy (CON) or intensive therapy (INT) (Table 1). CON
consisted of one or two daily injections of mixed intermediate and short-
acting insulins, daily self-monitoring of urine initially or later blood glucose,
and education about diet and exercise (31,32), but did not usually include
daily adjustments in the insulin dosage. INT included the administration of
insulin three or more times daily by injection or treatment with an external
pump. Insulin doses were adjusted according to the results of self-monitoring
of blood glucose performed four or more times per day, dietary intake, and
anticipated exercise. The goals of INT included preprandial blood glucose
70–120 mg/dl, postprandial 180 mg/dl, a weekly 3:00 A.M. measurement 65
mg/dl, and monthly A1C within the normal range (6.05%). Women who
became pregnant or were planning a pregnancy received INT until the time of
delivery. The DCCT was terminated prematurely in 1993, when it was
conclusively shown that intensive management delayed the development and
progression of retinopathy, nephropathy, and neuropathy (1). DNA was
collected (33), and participants gave written informed consent for its use.
These studies were approved by the institutional review boards of all
participating institutions.
A1C, glucose, and C-peptide measurements. DCCT subjects had A1C
measured centrally using a high-performance liquid chromatography
method once during eligibility screening and quarterly (CON) or monthly
(INT) during DCCT, for between 3 and 9 years (mean 6.5 years, Table 1)
(34). The stability of this assay over time has been described (34). The
mean quarterly A1C level in each CON participant during DCCT was 9.06%
(SD 1.24), based on an average of 26 measures (Table 1, supplementary Fig.
1). The mean monthly A1C measures in INT from DCCT year 1 onward was
7.22% (SD 0.96, supplementary Fig. 7). A centrally measured capillary
blood glucose daily proﬁle was obtained quarterly, consisting of seven
samples, obtained before and 90 min after each meal, and one before
bedtime, from which a daily mean was calculated. Stimulated C-peptide
was measured at screening for DCCT eligibility (35). CON subjects were
masked to their centrally measured A1C, glucose, and C-peptide results (31).
Further, at 82% of their visits, they were not adjusting their insulin dose in
response to self-monitoring of blood glucose (30).
Genotyping and quality control. We performed genome-wide genotyping in
DCCT subjects using the Illumina 1M beadchip assay (www.illumina.com, San
Diego, CA). Genotypes were called using BeadStudio using all individuals at
once. Data from three probands was excluded because of discrepancies
between reported sex and genotype data. No data were removed because of
low genotype call rate (minimum call rate threshold was 0.988). A total of 58
probands were removed because of disagreements between genotypes of
single-nucleotide polymorphisms (SNPs) from an earlier study (33). Geno-
types from 24 duplicate samples had an agreement rate of 99.9995%. Sample
contamination was assessed by calculation of the mean heterozygosity across the
genome for each individual, and using a range of 0.25–0.32, none were removed.
Consistency of genotypes with Mendelian inheritance was observed in 28 trios
with an observed rate of 99.71%. To detect cryptically related individuals and/or
sample mix-ups, identical-by-state estimates between all pairs of individuals were
performed (36), and two probands were removed. A total of 841,342 SNPs with a
minor allele frequency 1% were subsequently analyzed statistically.
Autosomal SNPs showing signiﬁcant association with sex (P  10
8)o r
deviating from the Hardy-Weinberg equilibrium (P  10
8) were excluded
from the analysis. To reduce the possibility of population stratiﬁcation, we
limited the analysis to individuals who self-identiﬁed as white and excluded
individuals who were determined to be admixed between Caucasian and other
ethnic groups through population genetic approaches (37), seeding with
genotype data from the three major populations genotyped in HapMap Phase
II (38). For this latter analysis, we ﬁrst removed SNPs from two regions known
to have strong linkage disequilibrium (major histocompatibility complex, the
polymorphic chromosome 8 inversion) and then selected independent SNPs,
required to have r
2  0.2 over a shifting window of 500 kb, yielding 98 K
SNPs. Principal components were selected based on a scree plot. In addition,
cluster plots of called genotypes by allele intensities for SNPs showing associa-
tion with outcomes were visually examined to ensure appropriate genotype
calling. Imputation of an additional 1,677,236 ungenotyped autosomal SNPs was
performed using release 22 Phase II CEU HapMap data (MACH v 1.0.16) and were
analyzed using genotype probabilities and an additive genetic model (MACH2QTL
v 1.04) (38,39). Genomic control lambda for mean A1C separately in CON, INT,
and combined (COMB) treatment groups were all 1.01.
Statistical analysis. We performed a ﬁve-stage analysis (supplementary Fig.
6). Given the level of multiple hypothesis testing, we required P values 5 
10
8 for genome-wide signiﬁcance in either the CON, INT, or COMB groups
(40) and one-sided P  0.05 for conﬁrmation in the other treatment group with
the same direction (41).
Stage 1 consisted of a genome-wide association study of the intra-
individual mean A1C during DCCT, undertaken separately in each treatment
group (667 CON individuals, 637 INT subjects) as well as in COMB including
treatment as a covariate (Table 1). For this initial screen, we calculated the
mean A1C from values obtained at eligibility screening, baseline, and up to 38
quarterly visits during DCCT for the conventional group. For INT and COMB,
we excluded data obtained during the introduction of intensive therapy in the
ﬁrst year of DCCT. These means were converted to normal scores and tested
for association with genotypes at each SNP using a 2df model, which does not
assume a particular genetic model. Imputed SNPs were analyzed in a linear
regression framework using the dosage of the imputed genotypes.
In stage 2, to identify loci that did not meet genome-wide signiﬁcance using
the mean A1C, but did so using the repeated measures, we tested the top SNPs
from stage 1 (P  10
4) using linear regression mixed models including all of
the available longitudinal A1C measures. In the intensive group, we used
monthly values. We analyzed the natural log transformation of the A1C values
with genotypes as a categorical variable and the time from DCCT eligibility as
a continuous covariate, specifying random intercept and slope, and assumed
an autoregressive moving average (1,1) covariance structure (because it had
TABLE 1
Descriptive information of 1,304 white DCCT subjects, separately
by treatment group
Conventional Intensive
Sex (n)
Male 363 332
Female 304 305
Cohort (n)
Primary prevention 344 307
Secondary intervention 323 330
Age at DCCT baseline (years) 26.5  7.1 27.2  7.1
Duration in the DCCT (years) 6.2  1.6 6.3  1.7
Eligibility A1C (%) 9.00  1.61 9.07  1.58
A1C measures obtained* 26  7 (5–40) 63  21 (3–103)
Mean A1C (%)* 9.06  1.24 7.22  0.93
Mean daily glucose from
seven-point capillary
proﬁle (mg/dl)* 231  80 156  50
Stimulated C-peptide at DCCT
baseline (pmol/ml) 0.117  0.119 0.111  0.119
Data are means SD and means SD (range) unless otherwise
indicated. There were 667 individuals in the conventional group and
637 in the intensive group with genotype data. *For the intensive
group, values used were from DCCT year 1 onward, whereas in the
conventional group, all DCCT values were used, and for A1C in the
conventional group, quarterly values were used, while in the inten-
sive group, monthly values were used.
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covariates and principal components from the Eigenstrat analysis was tested
by linear regression, with results based on type 3 sum of squares (SAS PROCs
REG and MIXED v9.1.3, Cary, NC).
In stage 3, SNPs achieving, or close to, genome-wide signiﬁcance in stage
2 were tested for association with the repeated mean daily glucose, as well as
C-peptide measured at eligibility screening for DCCT.
In stage 4, we analyzed the same SNPs with COMB A1C repeated measures,
including treatment group as a covariate, as well as testing for interaction
between each SNP and treatment.
Finally, since glycemia is a major risk factor for many diabetes complica-
tions, in stage 5, we tested the top A1C-associated SNPs for association with
the following: the prevalence of coronary calcium, conﬁrmed clinical neurop-
athy, hypoglycemia, as well as the time to event from DCCT baseline for three
retinal and two renal outcomes (supplementary Table 2). This was done
separately in each treatment group.
GoKinD. The Genetics of Diabetes in Kidneys (GoKinD) study was used to
replicate associations with A1C and nephropathy. GoKinD is a case-extreme
control study of renal disease in type 1 diabetes (42). Renal case and control
subjects were deﬁned as described elsewhere (42). Because, as expected the
single cross-sectional A1C was signiﬁcantly higher in renal case subjects than
control subjects, the associations with A1C were analyzed separately. In
addition, patients with a pancreas transplant were excluded from the A1C
analysis. Genotype data from the Affymetrix SNP 5.0 were used (43) and
imputed to HapMap phase 2 (release 24). Analyses were restricted to subjects
with Caucasian ancestry as determined by genetic analysis and in whom
appropriate genotype quality was observed.
MAGIC (Meta-Analyses of Glucose and Insulin-related traits Consor-
tium). We determined if any of the SNPs associated with A1C in DCCT were
also associated with A1C in nondiabetic individuals. For this purpose, we
obtained meta-analysis results for A1C from 23 genome-wide association
studies including 27,589–36,585 (depending on the SNP studied) nondiabetic
individuals of European descent (56) (see supplementary Methods).
RESULTS
To examine familial aggregation of A1C in type 1 diabetes,
use of the A1C measured at eligibility for DCCT probands
and A1C from sibs with type 1 diabetes (measured either
during the DCCT family study [44] or the Epidemiology of
Diabetes Interventions and Complications [EDIC] genetics
study [33]) revealed signiﬁcant familial correlation (Spear-
man rank correlation  0.33, P  1  10
3, n  95 pairs,
supplementary Fig. 14).
Stage 1: genome-wide association study of mean A1C.
To address potential population stratiﬁcation bias, we
tested for association of mean A1C with principal compo-
nents from Eigenstrat. When tested either individually or
together, none of the three principal components were
associated with mean A1C.
In the CON analysis, a single SNP (rs1358030, P  5 
10
9) on chromosome 10q25.1 met criteria for genome-
wide signiﬁcance (Table 2, supplementary Figs. 2 and 3),
with ﬁve other SNPs within a 35-kb region having P  10
2
(Fig. 1). SNPs in two other chromosomal regions also
attained evidence for association close to the genome-
wide signiﬁcance criteria in CON: one on chromosome 9
(rs10810632, P  4  10
7), with eight other SNPs within
a 20-kb interval (supplementary Fig. 11), and another on
chromosome 18 (rs163061, P  1  10
6), with no other
associated SNPs. At each of the top SNPs in these three
regions, the genotype-speciﬁc means were consistent with
an additive model in which individuals carrying the rare
allele had higher A1C (Table 2).
In the INT analysis, ﬁve SNPs on chromosome 15 had P
values of 5  10
7 (Table 2, supplementary Figs. 8 and 13).
The COMB analysis detected an additional SNP on chromo-
some 5, as well as the top CON chromosome 10 SNP (Table
2, supplementary Fig. 10). Analysis of imputed ungenotyped
SNPs did not reveal any additional loci that met genome-wide
signiﬁcance using the mean A1C. Results for all SNPs are
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Stage 2: repeated A1C measures. We selected the top
SNPs from stage 1 according to a P value 10
4 and
analyzed each of these 233 SNPs by mixed models using all
the repeated measures. In CON, chromosome 9 and 10
SNPs from stage 1 became more signiﬁcant (Table 3). In
the INT group, however, there was little improvement for
chromosome 15 SNPs over the analysis of the mean value
(Table 3). In COMB (Table 3), three additional SNPs in a
region on chromosome 14 approached genome-wide sig-
niﬁcance (P  3  10
7, supplementary Fig. 12). Analysis
of imputed SNPs did not provide evidence for additional
loci meeting genome-wide signiﬁcance (Table 3). Visual
inspection of cluster plots for the SNPs in Tables 2 and 3
conﬁrmed appropriate genotype calling (for rs1358030, see
supplementary Fig. 15). Of the loci from the literature that
were associated with glycemia in nondiabetic individuals,
only rs13266634 (SLC30A8) was marginally associated
with A1C in the DCCT, this being in the CON group (P 
0.03). This effect is in the same direction as the effect on
A1C in nondiabetic individuals (28) and the effect on risk
for type 2 diabetes (45) (N.B., supplementary Table 1).
Stage 3: repeated mean daily glucose measures and
C-peptide. Analysis of the 13 SNPs in Table 3, with
repeated mean daily glucose measures from all quarterly
measures during DCCT in the CON group, revealed asso-
ciations with SNPs in the chromosome 9 and 10 regions,
consistent in direction with their effect on A1C (Table 4).
There was also evidence for association of the chromo-
some 10 SNP with mean daily glucose in the INT group
(Table 4). This argues that SNP variation at these loci
inﬂuences A1C through effects on glucose. None of the
SNPs from Table 3 were associated with C-peptide mea-
sured at eligibility screening for DCCT (P  0.05).
Stage 4: repeated A1C measures in both treatment
groups with SNP treatment interaction. Testing for
SNP by treatment interaction provided strong evidence for
differences in the SNP associations between CON and INT
at the regions on chromosomes 9 (P  1  10
3) and 15
(P  3  10
4), weaker on chromosome 10 (P  0.01), but
no evidence on chromosome 14 (P  0.25, Table 4).
Stage 5: association of the 13 SNPs associated with
A1C with complications. We then tested the A1C-asso-
ciated SNPs (Table 3) for association with complications
in the same subjects and found several biologically con-
sistent associations of SNPs on chromosomes 9 and 10.
The chromosome 10 signal, rs1358030, was associated
with both time to persistent microalbuminuria (P  0.05)
and severe nephropathy (P  0.03) in CON (Table 5 and
supplementary Table 3). In COMB, rs1358030 was associ-
ated with the prevalence of coronary calcium (P  4 
10
3, supplementary Table 4). Even more striking, was
that in CON, this SNP was associated with hypoglycemia
either requiring medical assistance (P  1  10
4)o r
resulting in coma or seizure (P  1  10
3; Table 5 and
supplementary Table 5). Inclusion of the mean DCCT A1C
as a covariate in these later models reduced the associa-
tion of the SNP with hypoglycemia (P  0.03 and 0.02,
respectively), consistent with an effect being mediated
through glycemic control (supplementary Table 5). Simi-
larly, in CON, SNPs in the chromosome 9 locus were
associated with the following: time to persistent mi-
croalbuminuria (P  5  10
4), severe nephropathy (P 
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3, Table 6 and supplementary Table 3), mild
retinopathy (P  2  10
4), clinically signiﬁcant macular
edema (P  1  10
3), and severe retinopathy (P  2 
10
3, Table 6 and supplementary Table 6) as well as
hypoglycemia requiring assistance (P  4  10
3, Table 6
and supplementary Table 5). More modest results were
obtained for SNPs in the chromosome 14 and 15 regions
for time to mild retinopathy (P  0.01 and 0.02, respec-
tively, supplementary Table 6). The directions of these
associations at these three regions were consistent with
their effects on A1C, i.e., the genotype with higher A1C had
higher risk of renal, retinal, cardiac, and neuropathic
complications, while having lower risk of hypoglycemia
(Tables 5 and 6).
Conﬁrmation of rs1358030 associated with A1C in
GoKinD. We then tested the top 13 SNPs that were
identiﬁed from the four regions for A1C in DCCT for
association with A1C in GoKinD separately by case-con-
trol status. The mean  SD A1C in case subjects without
pancreas transplant was 8.29  1.56 (n  531), while in
control subjects, it was 7.47  1.15 (n  851). There was
nominal evidence for association of rs1358030 with A1C in
control subjects, but not case subjects (P  0.01 and P 
0.8, respectively). In the control subjects, the direction of
the effect at rs1358030 is consistent with that in DCCT,
with higher A1C values in individuals with more copies of
the rare allele (supplementary Table 7). Testing associa-
tion of the same 13 SNPs with renal disease, separately in
795 case subjects and 856 control subjects, revealed no
signiﬁcant evidence for association at any of the 13 SNPs
(P  0.1, supplementary Table 8).
Conﬁrmation of BNC2 association with A1C in non-
diabetic individuals. To determine if there was evidence
for association of the SNPs identiﬁed in DCCT with A1C in
nondiabetic individuals, we obtained summary statistics
from an analysis of A1C in 27.5 K nondiabetic individu-
als, carried out by the MAGIC investigators. There was
nominal evidence consistent with association at SNPs in
the chromosome 9 region (e.g., rs10810632, Table 7),
which is in the same direction as the association observed
with A1C in the DCCT CON group (Tables 2 and 3).
DISCUSSION
Using repeated longitudinal measures of A1C in the DCCT
and a multistage analysis, we identiﬁed a novel locus
(rs1358030) with genome-wide signiﬁcant association in
the conventional treatment group. This locus is also asso-
ciated with mean glucose during DCCT, arguing against a
speciﬁc effect on glycation of hemoglobin or red cell
survival. Analysis of repeated A1C in the intensive group
supported this locus at P  0.012, with additional support-
ive evidence in renal control subjects from the GoKinD
study (P  0.01).
None of the SNPs that were associated A1C were found
to be associated with C-peptide at DCCT baseline. Impor-
tant caveats to these negative results, however, are impor-
tant to remember, since the DCCT was not an inception
cohort of newly diagnosed type 1 diabetes, C-peptide
levels were an inclusion criteria, and it has been shown
that glycemic control inﬂuences persistence of C-peptide
(1,35,46).
The SNP with the most signiﬁcant association
(rs1358030) is 200 kb 3 from SORCS1 (sortilin-related
vacuolar protein sorting 10 domain containing receptor 1),
the nearest annotated gene. Because there are prior data
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we focus discussion below on SORCS1. A previous study
mapped a major locus for fasting plasma insulin levels to
a 242-kb interval containing only the promoter, ﬁrst exon,
and most of the ﬁrst intron of Sorcs1, using a conditioned
cross between mice carrying the “obese” Leptin mutation.
Between the two strains, 46 sequence differences were
identiﬁed in Sorcs1, including three nonsynonymous
changes, making it difﬁcult to ascribe phenotypic differ-
ences to a speciﬁc nucleotide change (47). Differences in
Sorcs1 expression in islets between the two strains were
documented (47). Independent data supporting SORCS1
as a locus for glycemic traits comes from a mapping study
that determined that Sorcs1 was the only gene in a major
locus for post-intraperitoneal glucose tolerance tests in a
rat model of diabetes (48). There was modest evidence for
association of SNPs in SORCS1, with a single measure of
fasting insulin in 574 nondiabetic Mexican Americans from
102 families (P  4  10
3). Further, in the Framingham
Heart Study, there was nominal association of rs1416406,
which is 120 kb 5 of SORCS1, with fasting insulin,
insulin sensitivity index, and insulin resistance (P 
0.02–0.005) (49). However, this SNP was not statistically
signiﬁcantly associated (P  0.4) with type 2 diabetes in
four replication studies. Importantly, neither of the SNPs
from these two studies (49,50) are in strong linkage
disequilibrium with rs1358030. Further, rs1358030 is not in
strong linkage disequilibrium with any other SNP geno-
typed in HapMap phase 2 or 3 (r
2  0.5, supplementary
Fig. 4) (38), arguing that it is either the etiological variant
or is in strong linkage disequilibrium with a causal variant
not genotyped in HapMap.
The regions associated with A1C on chromosomes 9
(BNC2), 14 (WDR72), and 15 (GSC) have not been previ-
ously shown to be associated with glycemic traits in
humans or animals. It is interesting to note that there is
evidence for conﬁrmation of the BNC2 region in a large
meta-analysis of A1C from nondiabetic individuals, sug-
gesting that some of the loci inﬂuencing glycemic control
in type 1 diabetes also inﬂuence glycemia in nondiabetic
individuals, consistent with twin studies (14). The associ-
ated SNPs in BNC2 are close to LOC648570, a hypothet-
ical gene.
Because of the larger “environmental” effect of INT
during DCCT, mean A1C was 1.8% lower than in the CON
group (Table 1), so INT cannot be considered a straight-
forward replication group for loci identiﬁed in CON (Table
4). Despite the concern that in the INT, subjects adjusted
insulin dose to achieve treatment aims, we speciﬁcally
show at the four loci that inclusion of insulin dose as a
covariate does not diminish the SNP association with A1C
(supplementary Table 9). If a genetic association depends
on the level of A1C, then evidence for association may
differ between the two groups. Moreover, overestimation
TABLE 6
Association of rs10810632 (BNC2) with complications in the DCCT/EDIC
Outcome
Conventional Intensive
OR or HR (95% CI) P OR or HR (95% CI) P
Hypoglycemia
Requiring medical assistance 0.49 (0.30–0.80) 0.004 1.02 (0.70–1.47) 0.94
Resulting in coma/seizure 0.60 (0.32–1.10) 0.10 0.89 (0.60–1.33) 0.58
Retinopathy
Mild nonproliferative retinopathy 1.73 (1.31–2.27) 0.0002 1.02 (0.77–1.35) 0.90
Severe nonproliferative retinopathy 1.83 (1.29–2.62) 0.002 0.61 (0.3–1.25) 0.15
Clinically signiﬁcant macular edema 1.87 (1.31–2.67) 0.001 0.97 (0.56–1.69) 0.92
Nephropathy
Persistent microalbuminuria 1.84 (1.31–2.59) 0.001 0.80 (0.46–1.41) 0.43
Severe nephropathy 1.85 (1.19–2.87) 0.01 0.32 (0.08–1.31) 0.06
Coronary calcium (
SE) 0.64  0.62 0.30 1.34  0.57 0.02
Conﬁrmed clinical neuropathy 1.64 (1.00–2.68) 0.05 0.69 (0.40–1.20) 0.6
See legend to Table 5. Additive coding of genotype, with the direction expressed as the number of copies of the C alleles (compared with
the T allele).
TABLE 5
Association of rs1358030 (SORCS1) with complications in the DCCT/EDIC
Outcome
Conventional Intensive
OR or HR (95% CI) P OR or HR (95% CI) P
Hypoglycemia
Requiring medical assistance 0.63 (0.50–0.80) 0.0001 0.89 (0.72–1.10) 0.28
Resulting in coma/seizure 0.60 (0.44–0.81) 0.001 1.05 (0.84–1.31) 0.64
Retinopathy
Mild nonproliferative retinopathy 1.15 (0.99–1.34) 0.07 1.16 (0.99–1.35) 0.07
Severe nonproliferative retinopathy 1.30 (1.04–1.63) 0.02 1.27 (0.92–1.77) 0.15
Clinically signiﬁcant macular edema 1.16 (0.92–1.46) 0.22 1.10 (0.8–1.5) 0.57
Nephropathy
Persistent microalbuminuria 1.25 (1.01–1.56) 0.04 1.25 (0.93–1.67) 0.14
Severe nephropathy 1.39 (1.04–1.87) 0.03 1.00 (0.61–1.64) 0.99
Coronary calcium (
SE) 0.83  0.36 0.05 0.68  0.35 0.02
Conﬁrmed clinical neuropathy 1.32 (1.01–1.73) 0.05 1.08 (0.81–1.43) 0.19
See supplementary Table 2 for deﬁnition of complications outcomes. Analysis was performed using additive coding of genotype, with the
direction expressed as the number of copies of the C alleles (compared with the T allele). HR, hazard ratio; OR, odds ratio.
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Winner’s curse (51), could explain a SNP-by-treatment
interaction (Table 4). Nevertheless, the ﬁndings on chro-
mosome 10 in repeated measures analysis of the intensive
group (P  0.012) argue for an effect in both treatment
groups, as well as GoKinD control subjects. The nonsig-
niﬁcant results in the GoKinD case subjects may be due to
lower power (estimated to be 43%).
Importance of repeated A1C measures. To emphasize
the importance of longitudinal measures in this study, we
compared the results from the stage 1 (mean A1C analysis)
with analysis of a single A1C measure (obtained at DCCT
eligibility screening) at the most signiﬁcant CON SNP
(rs1358030). The latter produced nominal signiﬁcance
(P  0.027) and accounted for only 0.61% of the variance
in 1,304 individuals. This compares to 5.2% (P  5  10
9)
of the variance in the former analysis (noting however that
this latter estimate may be upwardly biased [51]). We
calculated that 6,580 subjects (i.e., approximately ﬁve
times larger than DCCT) would be needed to detect a
comparable effect using a single A1C measure (5 
10
8,1
0.8) (52). These calculations, however,
assume 1) the mean A1C values from a contemporary
study would be similar to values at DCCT eligibility
(mean  9.0%) and 2) the genetic effect is similar across
the range of A1C values. Current clinical studies in type 1
diabetes report lower mean A1C levels than that observed
at DCCT eligibility (53). Further, in the conventional
group, the mean A1C dropped from 9.1 to 7.8% during
follow-up in EDIC (12). In addition, rs1358030 accounted
for only 1.7% of the variance in mean A1C in the
intensive group (compared with 5.2% in the conven-
tional group), consistent with a possible relationship
between effect size and A1C levels. Therefore, the
combination of these two factors could result in even
larger sample sizes being required for the same power to
detect a genetic effect using a single A1C measure in a
contemporary setting. This clearly emphasizes the ad-
vantage of exploiting longitudinal measures of variable
traits such as A1C, as has been described in other
studies (54).
In conclusion, although a major locus for A1C levels in
type 1 diabetes was identiﬁed, a number of outstanding
questions remain. These include evaluation in other
groups: nonwhite individuals, type 1 diabetic subjects who
do not meet DCCT eligibility criteria, and type 2 diabetic
subjects. SORCS1 is not a known susceptibility loci for
either type 1 or type 2 diabetes, nor does it overlap with
the loci identiﬁed for fasting glucose in nondiabetic indi-
viduals (Table 7) (20–23). Further, the etiological variants
and mechanisms by which genetic variation inﬂuences
glycemic control are unknown. Nonetheless, understand-
ing of genetic factors that inﬂuence an individual’s ability
to control their A1C levels has potential application to
clinical care and may provide insight into why patients on
the same regimen have different A1C values. In the future,
it may be possible to recommend different treatment or
regimen approaches to subjects based on genotype to
achieve similar targets. In the design and analysis of
genetic studies, attempting to identify risk factors for
long-term diabetic complications confounding by loci for
glycemic control may be reduced by inclusion of longitu-
dinal measures of A1C as covariates.
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Association results of top 13 SNPs from DCCT with A1C in the MAGIC study of nondiabetic individuals
Chromosome Position SNP Allele 1 Allele 2 Effect SE P Sample size
BNC2 gene region
9 16,779,024 rs10810632 t c 0.0220 0.0065 7.1  10
4 36,446
9 16,779,436 rs6475082 a g 0.0235 0.0064 2.7  10
4 36,557
9 16,779,878 rs4961760 t c 0.0194 0.0065 0.0030 35,837
9 16,791,850 rs2254193 a c 0.0235 0.0066 3.5  10
4 36,458
SORCS1 gene region
10 108,113,589 rs1358030 a g 0.0014 0.0036 0.70 35,304
GSC gene region
14 94,375,765 rs11624318 a c 0.0016 0.0042 0.71 35,801
14 94,405,244 rs11160219 a g 0.0018 0.0044 0.68 32,898
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WDR72 gene region
15 51,277,554 rs493218 t c 0.0015 0.0057 0.79 36,530
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Allele 1 indicates the effect allele compared with allele 2 as the reference. Alleles are aligned to HapMap forward strand, but are not aligned
in terms of minor or major allele. The A1C values were untransformed % National Glycohemoglobin Standardization Program
transformation: %A1C  91.48  (A1C/Hb) 	 2.152
, adjusted for age and sex.
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